Navigation Links
Silence Therapeutics Additional Listing
Date:12/20/2011

LONDON, December 20, 2011 /PRNewswire/ --

Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") a leading global RNA interference (RNAi) therapeutics company, today announces that application has been sought for 530,000 new ordinary shares of 1 pence each ("Ordinary Shares") to be admitted to trading on AIM. The new Ordinary Shares are being issued in accordance with a contractual agreement with Dr. Philip Haworth, former Chief Executive Officer of Silence.

It is expected that dealings in the new Ordinary Shares, which will rank pari passu in all respects with the existing issued share capital of the Company, will commence on 21 December 2011.

Notes for editors

About Silence Therapeutics plc (http://www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. Silence offers one of the most comprehensive short interfering RNA (siRNA) therapeutic platforms available today based on a strong intellectual property portfolio and large clinical safety database. Silence's clinical siRNA product pipeline is one of the broadest in the industry.

The Company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX™, DACC and DBTC. AtuPLEX enables the broad functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. The DACC delivery system allows functional delivery of siRNA molecules selectively to the lung endo-thelium with a long duration of target mRNA and protein knock-down. The DBTC delivery system enables functional deli
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
2. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
3. Silence Therapeutics Appoints New Vice President of Research
4. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
5. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
6. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
7. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
8. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
9. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
10. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
11. Silence Therapeutics Provides Corporate and Development Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 Research and Markets  has ... (SOFCs) - Global Strategic Business Report" report to their ... for Solid Oxide Fuel Cells (SOFCs) in US$ Thousands. The ... Canada , Europe , ... forecasts are provided for the period 2012 through 2020. Market ...
(Date:8/19/2014)... 2012, the European Union (EU) mandated use of the ICH-recommended ... – responding to the increasing need to understand and manage ... many regions, the main objectives of the PBRER are to:, ... of new or emerging information on the risks of a ... potential benefits of a drug; and , Allow ...
(Date:8/18/2014)... new therapy developed by researchers at the University ... and Columbia University Medical Center (CUMC) may help ... treatment. , The researchers demonstrated in a ... selectively inhibit blood vessel re-narrowing and simultaneously promote ... balloon catheter to open narrowed or blocked arteries. ...
(Date:8/18/2014)... August 18, 2014 Global HIV Infection ... report announced by Reportstack. The rate of HIV infection and ... a declining note at a positive rate across the globe. ... 2.3 million in 2005 to 1.5 in 2013, with the ... for such drastic changes in the infection rates has been ...
Breaking Biology Technology:Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... are continually reaching new lows as they reduce the temperatures ... low enough to overcome the entropy (a measure of the ... discovery of exotic states of ultra-cold matter. Now physicists at ... out of a collection of atoms in much the same ...
... Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ... Hardev Pandha of the Royal Surrey County Hospital, U.K., ... of Clinical Cancer Research. The paper is entitled "Synergistic ... Malignant Melanoma." , The research demonstrated that the innate ...
... , CAMBRIDGE, Mass., Sept. 24 Peptimmune, Inc. ... has formed a research and development collaboration with the Walter ... Research Center (NMRC), Silver Spring, MD to evaluate the Company,s ... dengue vaccines and point-of-care diagnostics. , , ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial 2Peptimmune to Collaborate on Dengue Virus Vaccine and Point-Of-Care Diagnostic With Two DOD Biomedical Research Facilities 2
(Date:8/19/2014)... UK 19 August 2014: An engineer at the ... despite not having a brain to communicate with the ... Harvard, Professor L Mahadevan, has developed a mathematical model ... view of how these soft bodied animals get around. ... the central pattern generator (CPG) which states that the ...
(Date:8/19/2014)... to treat pain, but its effect on pain ... a recent study reported on the Neural ... rat models of an avulsion injury to the ... neuropathic pain) were given electroacupuncture stimulation at bilateral ... (GB34). After electroacupuncture therapy, chronic neuropathic pain in ...
(Date:8/19/2014)... exist in different forms, they have not been widely ... Now researchers from the University of Surrey and Trinity ... elastic bands with graphene, to create a flexible sensor ... be made cheaply. , Once treated, the rubber ... graphene - which imparts an electromechanical response on movement ...
Breaking Biology News(10 mins):Secrets of how worms wriggle uncovered 2
... by Professor Hans-Georg Kräusslich at Heidelberg University Hospitals, ... Tumor Virology of the Deutsches Krebsforschungszentrum (German Cancer ... label Human Immunodeficiency Viruses (HIV) for visual investigations ... , The labeling permits scientists to observe the ...
... bugs, according to Gilbert Waldbauer, whose book "Insights From Insects: ... (Prometheus Books). , "We know a lot about pests, because ... professor emeritus of entomology at the University of Illinois at ... 2 percent are considered pests. Just as some plants growing ...
... synthesis of QS-21A, a medicinally important molecule that helps ... at the University of Illinois at Urbana-Champaign. , In ... the body's immune response in vaccine therapies against aggressive ... prostate cancer, HIV-1 and malaria. An extract from the ...
Cached Biology News:Virologists make major step towards understanding the process of HIV infection 2Bugs, even 'bad' ones, can be educationally beneficial, new book says 2Bugs, even 'bad' ones, can be educationally beneficial, new book says 3
Negative Control, eluted and packaged aseptically in 20l of 10mM Tris-HCL, pH 8.0, 1 mM EDTA, 5 years at either 4°C or -20°C...
AdestaTM Tissue/Cell Preservation Medium Sterile / Non-sterile: Sterility Tested Endotoxin: ...
...
... Clone/PAD: ZMD.440. Immunogen: Synthetic peptide derived ... PDGF-D (platelet derived growth factor D iris-expressed ... which differs from mouse and rat by ... with the ~50 kDa human mouse and ...
Biology Products: